A New York Times report highlights Texas’ decision to allocate $50 million to support clinical trials studying ibogaine, a psychoactive compound derived from a West African plant. The funding, approved through new legislation signed by the governor, is intended to support FDA-authorized research examining whether ibogaine could help treat conditions such as substance use disorder and post-traumatic stress disorder.
The initiative reflects growing interest among policymakers and researchers in evaluating new approaches to mental health and addiction treatment, particularly for veterans. Supporters argue that clinical trials are necessary to better understand ibogaine’s potential benefits and risks, while also determining whether it could eventually become an approved medical therapy.